What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version

Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a finer gradation. That does not mean you cannot escalate on a coarser schedule if that suits you — the published schedule is not a lower bound.

The dual agonism is not a marketing framing — GIP receptor and GLP-1 receptor engagement are both demonstrable. What is genuinely unresolved is how much of the clinical effect the GIP limb contributes, because no trial decomposes it.

Flagging that the sources on this are thinner than the confidence in the thread suggests.

Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.

Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly comparable in character. Individual variation is the largest factor.

This is where my knowledge stops and I would rather mark the edge than blur it.

Right — I had this wrong and I am glad to have read it before it mattered.

Picking up post #33: that is the part I would want checked first.

Worth stating the null on GIP component of tirzepatide before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.

The dual agonism is not a marketing framing — GIP receptor and GLP-1 receptor engagement are both demonstrable. What is genuinely unresolved is how much of the clinical effect the GIP limb contributes, because no trial decomposes it.

Old habit: I write down the expected answer before I calculate it.